Aura Biosciences

MA - BostonBiotechnology1 H-1B visas (FY2023)

Focus: Aura Biosciences is a Boston-based biotech company focused on delivering therapeutics via pseudo-viral vectors, with a concentrated pipeline in oncology and nephrology, particularly eye cancers. The company is pre-revenue and privately funded, operating at clinical stage with Phase 1-3 programs.

Oncology Nephrology

Profile data last refreshed 2h ago · AI intelligence enriched 2w ago

Open Jobs

0-1 this month

Stable — net -1 jobs in 30d

0 added, 1 removed. Backfill posture.

About Aura Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Aura Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Registry Study

Choroidal Melanoma

N/A

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Choroidal Melanoma

N/A

Clinical Trials (1)

Help build intelligence for Aura Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a novel platform: Aura's pseudo-viral delivery technology is differentiated and undercrowded, offering rare opportunity to build proprietary IP in a blue-sky modality.
Phase 3 momentum: belzupacap sarotalocan (Bel-sar) completed Phase 3 enrollment for choroidal melanoma (June 2026), positioning the company for near-term clinical readout and potential regulatory catalysts.
Tight, focused team: Only 3 open roles signal a lean operation where individual contributions drive strategy; strong H1B approval record (100% in 2023) suggests visa-friendly hiring.

Watch Out For

Pre-revenue exposure: No approved products, clinical-stage pipeline, and undisclosed funding/cash position create funding-dependent risk and uncertain runway.
Minimal hiring: Only 3 active roles (2 R&D, 1 Clinical) and sparse public disclosure on employee count and financials suggest early-stage scale and limited career mobility.

Generated by Claude from Aura Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT03941379A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

N/A

Observational

Choroidal Melanoma

N/A

Clinical Trials (1)

NCT07338968A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

N/A

Non-interventional, digital, patient-reported, real-world study

Choroidal Melanoma

N/A

Clinical Trials (1)

NCT07421739Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

N/A

Light-activated AU-011

Uveal Melanoma

Phase 1/2

Clinical Trials (1)

NCT03052127Study in Subjects With Small Primary Choroidal Melanoma

Phase 1/2

AU-011

Eye Cancer

Phase 2

Clinical Trials (5)

NCT06007690A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Phase 3

NCT04417530Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Phase 2

NCT06643884Suprachoroidal Administration in Subjects With Metastases to the Choroid

Phase 2

+2 more

belzupacap sarotalocan

Choroidal Melanoma

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 9 clinical trials

Top TAs: Oncology

H-1B (2023): 1 approval

Publications: 23 in PubMed

Therapeutic Area Focus

Oncology

9 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Private Funding (SEC Form D)

Jul 2020

Apr 2019

Dec 2018 (amended)

Jan 2018

Nov 2017 (amended)

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Re: Mattia Longoni, Leonardo Quarta, Donato Cannoletta, et al. Long-term Functional Outcomes and Decision Regret after Robot-assisted Radical Prostatectomy: An Experienced Surgeon Series. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.12.014.

European urology focus

2026

PMID:41558956

Re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2025.11.007.

European urology oncology

2026

PMID:41486041

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Aura Biosciences

About Aura Biosciences

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Aura Biosciences(10)

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Private Funding (SEC Form D)

Research Publications(10)